Unlocking new hope for Parkinson's disease treatment: the magical power of FGF8b

Unlocking new hope for Parkinson's disease treatment: the magical power of FGF8b

In the frontier exploration of neuroscience, Parkinson's disease, a difficult neurodegenerative disease, has always been the focus of scientists. It makes patients suffer from slow movement, stiffness and other pains, and the existing treatment methods have many limitations. However, in recent studies, a substance called fibroblast growth factor 8 (FGF8b) is bringing new hope for the treatment of Parkinson's disease.

The difficulty in treating Parkinson's disease is that the midbrain dopamine (mDA) neurons responsible for producing dopamine in the brain continue to die, and although current drugs can temporarily increase dopamine levels, they cannot prevent the continued death of neurons. Cell transplantation therapy has become a new hope, and human pluripotent stem cells (hPSCs) are considered to be the most potential cell source for producing mDA neurons. However, in the process of inducing hPSCs to differentiate into mDA neurons, how to avoid contamination by other types of neurons and ensure that pure and functional mDA neurons are obtained is a major problem faced by scientists. At this time, FGF8b came into everyone's field of vision.

FGF8b is like a precise "commander" and plays a key role in the differentiation of mDA neurons. Previous studies have found that it can reliably induce the expression of midbrain markers, which is an important feature of mDA neurons. However, FGF8b, the "commander", is also a little temperamental, and its effect is closely related to the time of use. In the early stage of mDA pattern formation, it is like a soldier who has not woken up yet, and the effect of enhancing the expression of midbrain markers is not obvious; but in the later stage, it will show its prowess and significantly increase the level of midbrain marker EN1.

However, FGF8b also has a headache side. It is like a double-edged sword. While inducing the generation of mDA neurons, it may also bring about cell type contamination of non-mDA neurons. This is like a carefully cultivated flowerbed suddenly mixed with some weeds, affecting the quality of the entire flowerbed. Scientists are well aware of this and have been working hard to find a better way to use it.

Recently, scientists have found a way to optimize the use of FGF8b through a large number of experiments and studies. They combined the biphasic activation strategy of WNT signaling to make FGF8b play the greatest role at the right time. Under this optimization scheme, not only the expression of midbrain markers was increased, but also the expression of other neuronal and non-neuronal lineage markers was minimized. The mDA neurons obtained after such treatment were highly close to normal mDA neurons in molecular, biochemical and electrophysiological properties.

Even more exciting is that the frozen stored mDA precursor neurons successfully restored the behavioral function of the damaged rats after being transplanted into the Parkinson's disease rat model. This is like lighting a bright light for patients in the dark, allowing us to see the great potential of FGF8b in the treatment of Parkinson's disease.

Although the application of FGF8b in the treatment of Parkinson's disease is still in the research stage, these research results have undoubtedly brought us new hope. I believe that with the unremitting efforts of scientists, FGF8b, the "magic commander", will lead us to find new ways to defeat Parkinson's disease and allow patients to have a healthy and beautiful life again.